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Abstract
Treating brain tumors using inhibitors of angiogenesis is extensively researched and tested in clinical trials.
Although anti-angiogenic treatment holds a great potential for treating primary and secondary brain tumors, no
clinical treatment is currently approved for brain tumor patients. One of the main hurdles in treating brain tumors
is the blood brain barrier - a protective barrier of the brain, which prevents drugs from entering the brain parench-
yma. As most therapeutics are excluded from the brain there is an urgent need to develop delivery platforms
which will bypass such hurdles and enable the delivery of anti-angiogenic drugs into the tumor bed. Such delivery
systems should be able to control release the drug or a combination of drugs at a therapeutic level for the desired
time. In this mini-review we will discuss the latest improvements in nano and micro drug delivery platforms that
were designed to deliver inhibitors of angiogenesis to the brain.
Introduction
It is now evident that solid tumors beyond a given
volume are dependent on the supply of oxygen and
nutrients from the vascular system, which has to grow
concomitantly with the tumor, similar to embryonic
development. This process, of newly developed blood
capillaries and blood vessels from pre-existing ones, has
been termed angiogenesis and enables the tumor not
only to increase its size but also its aggressiveness and
its ability to metastasize [1-4]. The process of angiogen-
esis is implicated not only in the pathology of tumors
but also in many other diseases including psoriasis [5,6],
age-related macular degeneration[7,8] and rheumatoid
arthritis [9].
Some of the most deadly malignancies that depend on
the angiogenic process for their growth are primary brain
tumors[10], among which glioblastoma multiforme
(GBM) represents 40% of all cases. GBM has been tar-
geted with many inhibitors of angiogenesis including tis-
sue inhibitors of matrix metalloproteinases[11-13],
chemokines [14-16], tyrosine kinase inhibitors [17-20],
interleukins [21,22], and naturally occurring proteolytic
fragments of large precursor molecules such as endosta-
tin, vasostatin, canstatin, angiostatin and others [23-29].
These molecules exert their inhibitory functions on
endothelial cells by multiple mechanisms including pro-
liferation, migration, protease activity, as well as the
induction of apoptosis [30]. Although such angiogenesis
inhibitors hold great promise, the ones that reached clini-
cal trials for brain tumor patients have failed to achieve
significant therapeutic outcome. One possible explana-
tion for this outcome that is supported by many
researchers is the lack of combinatory treatment with
standard chemo and radiotherapy [31]. Another obstacle
which may hamper the therapeutic outcome of anti-
angiogenic therapy is the blood brain barrier (BBB,
although destabilized in high grade GBM patients) which
therapeutics need to bypass to exert a significant brain
tumor inhibitory effect. The brain vasculature is predo-
minantly different that of other tissues as its principal
role is to prevent un-desirable and pathological sub-
stances from entering the brain parenchyma (Figure 1)
[32]. The physical properties of the BBB, which include
continuous tight junctions and low pinocytotic activity as
well as high electrical resistance (attributed to occludin
expression), form a tight barrier against materials with
high molecular weight and ionic substances that can
enter the brain parenchyma only through active transport
[33,34]. As such, the BBB hampers and complicates the
systemic delivery of therapeutics to the brain [35,36].
Small lipophilic drugs, which are expected to diffuse
across the BBB, are removed from the central nerve sys-
tem (CNS) by efflux transporters, such as P-glycoprotein
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multi-drug resistance include the multi-drug resistance-
associated protein (MRP) family (MRP1-MRP9) expre-
ssed in brain endothelial cells, breast cancer-resistant
protein (ABCG2) [38,39] and organic anion and cation
transporters (OAT and OCT respectively) [40,41].
Nonetheless, it is also possible that the method of
administration, which may destabilize the drugs, the
therapeutic level needed to reach the tumor or a combi-
nation of all the above hurdles contribute to the disap-
pointing outcome of such therapy approach.
These obstacles have resulted in a more urgent focus
on developing alternative delivery modalities, which may
bypass the BBB and efficiently target tumorangiogenesis
while protecting and stabilizing the drug until reaching
the tumor bed. These delivery modalities, may not only
solve the problem of the BBB permeability and the need
for a combinatorial treatment, but also reduce the thera-
peutic amount of drug needed to be delivered to the
tumor, thus lowering toxicity and side effects of the
drugs. Nevertheless such delivery modalities, whether
local or systemic, have to deliver the therapeutics to the
tumor mass, where the diffusion and distribution of the
drug is governed by abnormal high tumor cell density,
high interstitial fluid pressure within the tumors and
leakiness of tumor microvasculature, resulting in fast
clearance of the diffusing drug [42,43].
In this review, we will discuss the progress made in
designing and developing different nano and micro drug
delivery platforms that aim to bypass the BBB and deliver
systematically or locally therapeutics that target brain
tumor angiogenesis. Table 1 summarizes the current
clinical status of therapeutics, which are also utilized in
studies aimed to develop drug delivery platforms for
brain tumor therapy as will be discussed later on.
Local drug delivery platforms
Local delivery to the brain utilizes BBB disruption, as
well as local implantation of the delivery system directly
in the tumor bed. These delivery systems which include
cerebral infusion methods, polymeric nano-particles,
wafers and more, are comprehensively studied and
represent promising approaches for the delivery of drugs
to the brain.
Intra-arterial cerebral infusion
Intra-arterial cerebral infusion involves the insertion of
micro-catheters into the small arteries of the brain via
the carotid artery [44]. This unique approach was used
to infuse mannitol into the area of interest for transient
disruption of the BBB, followed by the infusion of a
therapeutic such as bevacizumab. As bevacizumab is
selectively delivered to brain tumors, larger amount of
the drug may be used when compared to the amount of
drug used by intravenous administration of bevacizumab
resulting with reduced side effects [44]. This delivery
system may also enable the direct delivery of other
drugs, which target the angiogenic processes in brain
tumors.
Polymeric particles
Another popular approach, which is still in preclinical
studies, is based on polymeric nano and micro-particles
using polymers such as poly(butyl cyanoacrylate), Poly
(ethylene-glycol), Poly(lactic-co-glycolic) acid, Poly-
glycerol and others [45-48]. These particles can be
loaded with or attached to different therapeutics and
can then be delivered directly to the tumor site. The use
of particle platforms significantly reduces (in some cases
more than 50 folds) the amounts of drugs needed to
reduce tumor volume and weight when compared to
systemic administration. Such platforms need to be
carefully designed, taking into account the properties of
Figure 1 Comparison between cerebral and noncerebral blood
vessels. Cerebral blood vessel has tight junctions, which do not
allow the passage of un-desirable and pathological substances to
the brain parenchyma while non cerebral blood vessel allows better
diffusion of drugs. Targeting the brain can be achieved using the
drug itself or by using drug delivery platforms that release the drug
at a specified location.
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preparation method, manufacturing costs, biodegradabil-
ity and its pharmaceutical qualities (stability of the ther-
apeutic, dosage capability, distribution and site specific
targeting). These delivery vehicles must also retain the
biological activity of the drug and allow its sustained
release over extended periods of time when needed [49].
This is particularly important when attempting to deli-
ver endogenous inhibitors of angiogenesis as opposed to
chemotherapeutic drugs.
PLGA particles
One of the widely used polymers for the design of dif-
ferent delivery platforms is the poly-lactic-co-glycolic
based polymer (PLGA). The huge advantages of delivery
formulations based on PLGA, are their non immuno-
genicity and the ability to control the release profile of
the drugs by manipulating the ratio of lactic to glycolic
acids. An interesting publication by Shahani et al.
showed that curcumin encapsulated in PLGA micro-
spheres down regulates markers of angiogenesis such as
CD31 and vascular endothelial growth factor (VEGF) in
nude mice bearing MDA-MB-231 xenografts. Further-
more, curcumin levels in the brain were 10 to 30 folds
higher than in blood indicating the possibility to use
this formulation to treat brain tumors [50]. Arai et al.
showed the feasibility of using thermoreversible gelation
polymer combined with doxorubicin loaded PLGA
microspheres or liposomes for local treatment of malig-
nant glioma [51]. PLGA microspheres have also been
used to carry glioma cell lysates for the induction of
protective immunity in rat glioma model. Although this
system was less efficient than irradiated cell lysate it
does exhibit adjuvant properties [52].
In our lab, PLGA has been used to produce particles
loaded with PEX, a fragment of matrix metalloproteinase
(MMP)-2, or platelet factor 4 fragments (PF-4/CTF) for
the delivery of these angiogenesis inhibitors to glioma
bearing nude mice (Figure 2). PEX was detected and iso-
lated from the culture medium of several cell lines and
acts as inhibitor of angiogenesis, cell proliferation and
migration, demonstrating a 99% suppression of glioma
tumor growth in human glioma xenografts [13]. PF-4 is a
strong anti-angiogenic factor that inhibits angiogenesis
by blocking FGF-2 binding to endothelial cells [16,53].
PEX and PF-4/CTF administered in this mode showed
88% and 95% reduction in tumor volume 30 days post
treatment, respectively, demonstrating the advantage of
PLGA microspheres for angiogenesis inhibitor delivery to
glioma tumors [49].
Other drugs and proteins encapsulated in PLGA micro-
spheres for the treatment of glioma include temozolomide
[54], paclitaxel [55], imatinib mesylate for treating intra-
cranial glioma xenografts [56], BCNU as an alternative for
Gliadel [57], cisplatin [58], mitoxantrone [59] interleukin-
18 [60] and 5-Fluorouracil [61,62].
Wafers
Wafers are composed of biodegradable polymers that deli-
ver the drugs into brain tumors via local administration,
Table 1 FDA approved or under clinical trails drugs for brain tumors therapy
Drug FDA approved for brain tumors/
Brain clinical trails
Approved routes of administration (Brain
tumors & other disorders)
Drug delivery platforms in research for
approved drugs
Temozolomide Approved Oral Intracerebral Biodegradable gel matrices/
Polymer nanoparticles
Procarbazine Approved Oral -
lomustine Approved Oral Liposomes/Microcapsules
Vincristine Approved IV Intra-arterially
Carmustine Approved IV/Oral/Wafer CED/Polymer microchips and
microspheres
Carboplatin Approved IV CED/Intracerebral/Intraarterial/Liposomes
Bevacizumab Approved IV Intra-arterial
Doxorubicin Phase I/II/III injection;liposomal * -
Imatinib
mesylate
Phase I/II/III Oral; Intravenous * -
Cisplatin Phase I/II/III Injection * -
Topotecan Phase I/II/III Injection; Oral * -
Interferon-
alpha
Phase I/II Injection; Subcutaneous; Oral * -
Paclitaxel Phase I/II Intravenous; Injection * -
Arsenic
trioxide
Phase I/II Injection * -
* These routes are approved for other disorders.
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the delivery of angiogenesis inhibitors alone or in combi-
nation with other chemotherapeutic drugs.
The first device approved by the FDA was Gliadel®, a
polymeric wafer designed for the delivery of carmustine
[63]. Gliadel® is placed directly in the brain cavity cre-
ated by the resection of the tumor. Clinical studies with
Gliadel have shown increased survival rates in newly
diagnosed malignant gliomas patient particularly when
combined with a chemo-treatment [64,65]. Due to the
fact that not all of GBM patients are responsive to car-
mustine there is a need to evaluate other drugs for the
treatment of GBM patients [66].
Cell delivery platform
Different studies have attempted to use cells, particularly
stem cells, that are engineered to secret inhibitors of
angiogenesis for brain tumor therapy [67,68]. Another
approach, which is based on cell delivery, is polymeric
cell encapsulation. The encapsulation system consists of
viable cells surrounded by a non-degradable, selectively
permeable barrier that physically isolates the trans-
planted cells from host tissue and the immune system.
This platform relies on host homeostatic mechanisms
for the control of pH, metabolic waste removal, electro-
lytes and nutrients. One of the most studied cell micro-
encapsulation methods has been based upon alginates,
which are polysaccharides extracted from various species
of brown algae (seaweed) and purified to a white pow-
der. The alginates have different characteristics of
viscosity and reactivity based on the specific algal source
and the ions in the solution. Alginate has also hydrophi-
lic properties, which minimize protein adsorption and
cell adhesion, thus exhibit a high degree of biocompat-
ibility. For cell encapsulation, the alginate gel is further
complexed with polycations such as Poly-L-Lysine (PLL)
to form a semi-permeable membrane, which allows the
delivery of different bioactive substances to the sur-
rounding while preventing the diffusion of antibodies
and other components of the immune system. Cell
encapsulation has been used for broad therapeutic appli-
cations such as delivery of neuroactive agents for the
treatment of age-related degeneration [69,70], Alzhei-
mer’s disease[71-74], amyotrophic lateral sclerosis
[75,76], neuroprotection [77], Huntington’s disease
[78,79] and Parkinson’s disease[80-82]. This approach
has also been used to deliver inhibitors of angiogensis to
glioma tumors. Read et al. showed that human fetal kid-
ney 293 cells expressing endostatin, an anti-angiogenic
20 kDa fragment of collagen XVIII, encapsulated in
sodium alginate, and intracerebral injected near BT4C
glioma bearing rats prolonged the survival of the ani-
mals by 84% due to induction of apoptosis, hypoxia and
large necrotic avascular areas [24,83]. Endostatin
released from such delivery system, reduced the func-
tionality and the diameter of blood vessels as well as
tumor cell invasion as shown by intravital microscopy
[84]. Bjerkvig et al. also used the same methodology to
deliver endostatin into rat brains [85].
Joki et al. demonstrated the encapsulation of baby
hamster kidney cells (BHK-21) engineered to secrete
human endostatin, for the inhibition of glioblastoma
xenograft in nude mice [24,86]. In our lab, Goren et al.
showed that encapsulation of human mesenchymal stem
cells (hMSCs), known to be hypo-immunogenic, within
alginate-PLL micro-capsules (Figure 3), led to a 3-fold
decrease in cytokine expression making them the cell of
choice for micro encapsulation cell based-therapy. In
this system, the hMSC were genetically modified to
express PEX and their injection adjacent to glioblastoma
bearing nude mice had led to 87% and 83% reduction in
tumor volume and weight, respectively [87]. Feasibility
of encapsulated cells to produce single-chain TRAIL has
been shown by Kuijlen et al. using intracerebral implan-
tation of these capsules in mice brains [88]. Cell encap-
sulation for CNS malignancies is reviewed in more
detailed by Visted et al [89].
Convection-enhanced delivery
Convection-enhanced delivery (CED) was developed to
overcome poor brain drug distribution. CED uses hydro-
static pressure to deliver drugs via a catheter located
within or around a tumor. As poor drug diffusion
through the brain interstitium restricts intratumoral
Figure 2 PLGA particles loaded with therapeutic. PLGA particles
(50:50 lactic to glycolic), labeled with 6-coumarin and loaded with
rhodamine labeled PF-4/CTF.
Gilert and Machluf Journal of Angiogenesis Research 2010, 2:20
http://www.jangiogenesis.com/content/2/1/20
Page 4 of 11drug administration, fluid convection within the brain
(under pressure gradient), can greatly enhance the dis-
tribution of molecules in the tumor area. Distribution of
drugs via CED is not restricted to white matter and
penetration into gray matter can be observed 24 hours
after infusion [90]. Nonetheless, Real-time monitoring of
CED variability in efficacies as well as limited distribu-
tion of the drug still need to be addressed [91].
Saito et al. used CED to deliver topotecan entrapped
in nano-liposomes (liposomes as drug delivery system
will be further discussed in this review in a separate sec-
tion). CED of liposomal topotecan exerted strong anti-
angiogenic activity and disruption of tumor vessels. This
delivery platform enabled inhibition of angiogenesis at
low concentrations of the therapeutic and demonstrated
the ability to deliver anti-angiogenic drugs via CED sys-
tems [92]. In another study, Ohlfest et al.u s e dC E Dt o
co-deliver soluble vascular endothelial growth factor
receptor (sFlt-1) and angiostatin-endostatin fusion gene
transposons into intracranial glioma model achieving
anti-angiogenic effect [93].
Systemic drug delivery platforms
Systemic drug delivery to the brain requires the considera-
tion of the BBB as previously discussed. More over, sys-
temic delivery systems need to overcome other obstacles
such as protein adsorption, enzymatic digestion and
engulfment of the delivery particles by phagocytic cells
when using 300 nm-10 micrometer particle sizes. None-
theless, systemic administration can have the benefit of
non-invasiveness when compared to local administration
using intracranial surgery. Different delivery systems have
been developed to achieve systemic therapeutic targeting
to the brain including pegylation of drugs, liposomes, poly-
meric nano-particles, dendrimers and bionanocapsules.
We will discuss some of these designed nano-sized deliv-
ery systems, which may enable the delivery of drugs to the
brain via systemic administration.
Drug Pegylation
One simplified approach designed to bypass the BBB is
the modification of a drug by a polymeric composite,
which some term as nano vehicles and other as drug con-
jugates. One example is the pegylation of interferon-
alpha, which is known for its anti-angiogenic effects on
tumors and other angiogenic diseases such as AIDS-
related Kaposi sarcoma [46]. The motivation behind the
pegylation of interferon-alpha was to both reduce its neu-
rologic and immune system toxicities and to improve its
circulation time [46,48,94,95]. Pegylation of interferon
alpha resulted in a long-lasting form of interferon that
may target angiogenesis in glioma [94]. Pegylation has
also been used on camptothecin and doxorubicin,
improving their solubility, circulation time and lowering
their toxicity [96,97].
Liposomes
Liposomes are one of the most popular nano-system
designs for systemic drug delivery. Liposomes are
defined as delivery vehicles composed of phospholipids
bilayers (one or more) ranging from tens to hundreds of
nanometers in diameter (Figure 4). Liposomes’ structure
enables the entrapment of water soluble drugs at the
aqueous core of the system, while hydrophobic drugs
can be entrapped in the lipid bilayer composed of syn-
thetic or natural lipids [98]. Liposomes have been widely
researched for their ability to deliver proteins [99], che-
motherapeutics [100,101], RNA [102,103], DNA [104]
and other therapeutics. Their advantages include bio-
compatibility, low toxicity, enhanced efficacy of the
encapsulated drugs and reduced side effects [105]. Fun-
damental disadvantage of conventional liposomes is
their rapid removal from blood circulation by the mono-
nuclear phagocyte system (MPS). Although this charac-
teristic can be exploited to deliver drugs into phagocytic
cells, it hampers the liposomal abilities to target the
therapeutic to other cells and organs[106]. Liposomal
clearance from the blood circulation is due to recogni-
tion of surface bounded opsonins by the MPS [107,108]
and membrane lysis of charged liposomes by comple-
ment components [109]. One approach to extend lipo-
some circulation time and bypass such fast blood
clearance, is to anchor Poly(ethylene glycol) (PEG), to
the liposomal membrane- rendering them as stealth
Figure 3 Cell encapsulation platform. Human mesenchymal stem
cells (hMSCs) labeled with the mCherry fluorescence marker
engineered to express PEX and encapsulated in alginate capsules.
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tions also decreases aggregation and reduces interactions
with plasma proteins thus increases their circulation
time [111,112]. In gliomas, the BBB is disrupted at the
site of the malignant lesion and the leaky endothelium
enables passive convective transport of liposomes into
the brain. Studies show that stealth liposomes extrava-
sate into the extracellular space forming clusters and
acting as a reservoir within the tumor area [113,114].
Caelyx® is a novel formulation of stealth® liposomal dox-
orubicin. A study with 10 patients with metastatic brain
tumors and five patients with brain glioblastoma under-
going radiotherapy confirmed intense accumulation of
radio-labeled Caelyx® in the brain tumor as compared to
the normal brain tissue[115]. In another study, doxoru-
bicin encapsulated in liposomes exhibited break down of
tumor vasculature [116]. Other drugs encapsulated in
liposomes for treating brain tumors include taxol [117]
and arsenic trioxide which down-regulated the expres-
sion of VEGF [118].
Polymeric nano-particles
Polymeric nano-particles (1-999 nano-meters) have
attracted much attention as vehicles for systemic drug
delivery due to their biocompatibility and stability proper-
ties. The diversity of materials, mostly synthetic, used to
formulate nano-particles include poly(butyl cyanoacrylate),
Poly(ethylene-glycol), Poly(lactic-co-glycolic) acid, Poly-
glycerol and others [45-48]. Hekmatara et al. showed that
doxorubicin bound to polysorbate-coated nano-particles
made of Poly(butyl cyanoacrylate) and injected intrave-
nously into tumor bearing Wistar rats, had a drastic effect
on vessel density with neither neuronor systemic toxicity
[45]. Another approach that might be feasible for
brain tumor targeting is a novel delivery system termed
‘nanocell’. This delivery system is composed of nuclear
nano-particle enveloped with pegylated-phospholipid
block-copolymer [95]. The idea behind this system is to
deliver inhibitors of angiogenesis followed by the delivery
of cytotoxic drugs into the tumors. In this system, the
angiogenic inhibitor is located within the lipid layer and
the chemotherapeutic drug is incorporated to the nano-
particle. Sengupta et al. showed that doxorubicin conju-
gated to the copolymer poly-(lactic-co-glycolic) acid
(PLGA) enveloped within PEG distearoylphosphatidyl-
ethanolamine (PEG-DSPE), phosphatidylcholine and cho-
lesterol in an optimal ratio with combretastatin (which
causes rapid vascular shutdown) had significant effect on
tumor vasculature [95]. Another interesting approach for
targeting angiogenesis is the use of RNA-based inhibitors
[31]. Glioma angiogenesis has being targeted by RNA-
based inhibitors, which include short hairpin RNAs
(shRNAs) and short interfering RNAs (siRNAs) against
urokinase-type plasminogen activator and MMP-2 respec-
tively [119-121]. These studies showed significant anti-
angiogenic effect and impaired glioma invasion in mouse
models. Recently, microRNAs (miRNAs), a new group of
RNA inhibitors, have attracted much attention as unlike
siRNAs and shRNAs they can interact with many mRNAs
due to incomplete nucleotide complementarities [122].
One such group of miRNAs was related to angiogenesis
[123]. Ofek et al. developed a novel polymerized polygly-
cerol-based cationic dendrimer core shell structures,
which can deliver siRNAs to cells and inhibit angiogenesis
[47]. These siRNA-dendrimers improved the stability,
uptake and intracellular trafficking of siRNAs demonstrat-
ing in-vivo targeting of luciferase in luciferase-expressing
tumors in mice [47]. In another study, Schneider et al.
showed that poly-(butyl cyanoacrylate) nano-particles
coated with Polysorbate-80 were capable of delivering
antisense oligonucleotide, specifically against TGF-b2, into
intracerebral tumors via the BBB [48,124].
A different concept of nano-delivery system has been
recently introduced and termed ‘bionanocapsules’ [125].
Bionanocapsulses are hollow nano-particles with an
average diameter of 80 nm, displaying specific affinity to
human hepatocytes via the pre-S1 peptide displayed on
their surface and have successfully delivered peptides,
genes and siRNA to the liver [125]. Tsutsui et al.
demonstrated that the deletion of the pre-S1 peptide
and conjugation of the anti-human EGFR, recognizing
EGFRvIII, abolished hepatocytes targeting, making them
Figure 4 Liposomes. TEM image of liposomes made of DOPE -1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine, DMPA -1,2-dimyristoyl-
sn-glycero-3-phosphate, POPE - 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine and POPC - 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine.
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[126]. These studies suggest a new drug delivery system
for brain tumor and possible use of such delivery sys-
tems for the delivery of anti-angiogenic drugs should be
considered.
Optimizing therapeutic delivery using bio-
mathematical models
Mathematical models are based on the optimization of
natural algorithms within the growing biomathematical
tool kit and can provide a deeper understanding of the
dynamic biological process involved with tumor angio-
genesis, tumor growth or other tumor properties. Using
mathematical modeling, tumor behavior upon drug
treatment (free or released), from a delivery platform
can be predicted. This is a powerful tool that can mini-
mize invasive protocols, reduce drug quantities, force
combinational drug treatments and reduce the number
of animals required for in-vivo experiments.
These methodologies have already been applied in the
fields of cancer chemotherapy and cancer immunother-
apy with minimization of tumor burden as their primary
objective [127-130] and may be of great importance
when considering GBM treatments. Gevertz et al.
described for the first time, a biomathemathical model
for the follow up of GBM growth, which is based on the
evolution of the tumor microvasculature and mass. In
this model they assume that the key players in glioma
angiogenesis are VEGF, Ang-1 and Ang-2 (Angiopoie-
tins) and were able to show that an “angiogenic switch”
is valid, just as Folkman predicted [131,132]. Kronik
et al. successfully created a mathematical model which
describes the growth rate of high grade gliomas post sti-
mulation of alloreactive CTLs. The mathematical analy-
sis shows that differences in the growth rate parameter
alone suffice for explaining the difference in the success
of cellular immunotherapy treatment for grade III and
grade VI glioma patients [133].
In our lab, Benny et al. presented a pre-clinical study
that used PLGA microspheres loaded with imatinib
mesylate in GBM model in mice [56]. Together with
Kronic et al., we were able to extract, using mathemati-
cal modeling, the pharmaco kinetics of imatinib mesy-
late, which correlated significantly with the kinetics
obtained experimentally (unpublished data). The models
allow us to predict the release of drug in the intracranial
environment, its clearance and the therapeutic window
needed for additional administration of the loaded
PLGA particles.
Conclusions
Targeting brain tumor angiogenesis is a promising
approach to arrest tumor growth. Nonetheless, clinical
studies with inhibitors of angiogenesis have produced
disappointing results. This may be due to the fact that
these inhibitors were administered alone, without
standard chemo and radiotherapy. It is also strongly
possible that the way of administration (mostly intrave-
nously), drug stability and quantities needed to achieve
therapeutic outcome, hamper the therapeutic potential
of such group of drugs. More over as the brain is a
unique organ, protected via the BBB and efflux trans-
porters (although disrupted in high grade glioma
patients), the drugs need to bypass such barriers and
reach the tumor in a therapeutic dosage. Therefore
developing drug delivery platforms that bypass such
barriers and target the therapeutics to the tumor site
a n do nt h eo t h e rh a n ds t a b i l i z ea n dp r o t e c tt h ed r u g
until it is released near or in the tumor bed can result
in surprising therapeutic effects for such group of
inhibitors.
The progress made in the field of biomaterials
together with the pharmaceutical field, contribute vastly
to the development of such local and systemic delivery
platforms.
Yet, regardless of the enormous advantageous that
these technologies can offer, the road to clinical studies
using these platforms is still facing problems, which
need to be studied and solved as they target the most
protected and closed organ, the brain. Selection of poly-
mers, preparation methods, drug loading and release
profile, clearance of the drugs and immune aspects need
to be taken in account and studied carefully to pave the
way for new and promising delivery platform to reach
the clinical setting.
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